Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod

  • The European Commission (EC) has approved Merck & Co Inc's  MRK soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). 
  • Verquvo (2.5 mg, 5 mg, and 10 mg) is indicated to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy. 
  • Merck has the commercial rights to Verquvo in the U.S., and Bayer AG BAYRY has the exclusive commercial rights in the rest of the world.
  • In January, the FDA approved Verquvo.
  • Price Action: MRK shares are up 0.42% at $76.49 during the premarket session on the last check Wednesday.
  • Related content: Benzinga's Full FDA Calendar.

Posted In: BriefsEuropean Medicines Agency (EMA)BiotechNewsHealth CareFDAGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.